Patient characteristics, treatment patterns and disease burden in people with Parkinson's disease: insights from the Parkinson's disease real-world impact assessment (PRISM) study

被引：0

作者：

Foltynie, T. ^{[1
]}

Tolosa, E. ^{[2
]}

Ferreira, J. J. ^{[3
]}

Antonini, A. ^{[4
]}

Lees, A. ^{[1
]}

Ebersbach, G. ^{[5
]}

Rascol, O. ^{[6
]}

Rocha, J. -F. ^{[7
]}

Magalhaes, D. ^{[7
]}

Soares-Da-Silva, P. ^{[8
]}

机构：

[1] Natl Hosp Neurol & Neurosurg, Dept Clin & Movement Neurosci, London, England

[2] Univ Barcelona, Hosp Clin, Parkinson Dis & Movement Disorder Unit, Barcelona, Spain

[3] Univ Lisbon, Lab Clin Pharmacol & Therapeut, Fac Med, Lisbon, Portugal

[4] Univ Padua, Dept Neurosci, Padua, Italy

[5] Beelitz Hosp, Movement Disorders Clin, Beelitz, Germany

[6] Univ Toulouse, Dept Neurosci & Clin Pharmacol, Toulouse, France

[7] BIAL Portela & Ca SA, Global Parkinsons Dis Dept, Coronado, Portugal

[8] BIAL Portela & Ca SA, Res & Dev Dept, Coronado, Portugal

来源：

EUROPEAN JOURNAL OF NEUROLOGY | 2020年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

O1024

引用

页码：17 / 18

页数：2

共 50 条

[31] Real-World Utilization of Istradefylline Among Patients with Parkinson's Disease
Rezak, M.
Qian, J.
Zhao, Y.
Silverstein, A.
Chamber, J.
Swindle, J.
Kronfeld, N.
LeWitt, P.
MOVEMENT DISORDERS, 2023, 38 : S622 - S622
[32] Treatment patterns in people with Parkinson's disease in the United States and the association with cardiovascular disease
Rutten-Jacobs, Loes C. A.
Roumpanis, Spyros
Liu, Yutong
Coloma, Preciosa M.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 251 - 251
[33] PATIENT CHARACTERISTICS AND TREATMENT STATUS IN PARKINSON'S DISEASE (PD)
Grubb, E.
Castelli-Haley, J.
Treglia, M.
Lage, M. J.
VALUE IN HEALTH, 2012, 15 (07) : A558 - A558
[34] Caregiver burden of patients with Parkinson's disease and the impact on disease duration
Lökk, J.
MOVEMENT DISORDERS, 2006, 21 : S482 - S482
[35] The treatment of Parkinson's disease in older people
Lien, CTC
Mutch, WJ
SCOTTISH MEDICAL JOURNAL, 1997, 42 (05) : 147 - 150
[36] TREATMENT OF PSYCHOSIS IN PARKINSON'S DISEASE AND PARKINSON'S DISEASE DEMENTIA
Ballard, Clive
Mills, R.
Williams, H.
Corbett, A.
Cummings, J.
NEUROBIOLOGY OF AGING, 2014, 35 : S2 - S2
[37] Impact of Comorbidities on the Burden for Patients with Parkinson's Disease
Ward, Alex
Michels, Shannon L.
Lanes, Stephan
Gilmore, O'Neill N.
Spyros, Papapetropoulos
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2010, 19 : S254 - S254
[38] Association of real-world wearable mobility measures with Parkinson's disease severity and disease progression
Mirelman, A.
Volkov, J.
Solomon, A.
Gazit, E.
Nieuwboer, A.
Del Din, S.
Rochester, L.
Avanzino, L.
Pelosin, E.
Bloem, B.
Della Croce, U.
Cereatti, A.
Thaler, A.
Shirvan, J.
Cedarbaum, J.
Giladi, N.
Hausdorff, J.
MOVEMENT DISORDERS, 2023, 38 : S786 - S786
[39] THE IMPACT OF PATIENT AGE ON PATTERNS OF DIAGNOSIS AND TREATMENT AMONG PATIENTS WITH PARKINSON'S DISEASE
Grubb, E.
Lage, M. J.
VALUE IN HEALTH, 2012, 15 (04) : A150 - A150
[40] The impact of patient sex on patterns of diagnosis and treatment among patients with Parkinson's disease
Grubb, B.
Lage, M. J.
MOVEMENT DISORDERS, 2012, 27 : S482 - S482

← 1 2 3 4 5 →